Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mast cell-based molecular subtypes and signature associated with clinical outcome in early-stage lung adenocarcinoma.

Molecular oncology - 1 May 2020

Bao Xuanwen, Shi Run, Zhao Tianyu, Wang Yanfang

Abstract excerpt

Mast cells are a major component of the immune microenvironment in tumour tissues and modulate tumour progression by releasing pro-tumorigenic and antitumorigenic molecules. Regarding the impact of mast cells on the outcomes of patients with lung adenocarcinoma (LUAD) patient, several published studies have shown contradictory results. Here, we aimed at elucidating the role of mast cells in early-stage LUAD. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Databases, Genetic
Share to Gene Ontology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Kaplan-Meier Estimate

Share to Mast Cells

Share to Neural Networks, Computer

Share to Proto-Oncogene Proteins c-myc

Source

Open in PubMed Open full text

Identifiers

PMID: 32175651
DOI: 10.1002/1878-0261.12670
PMCID: PMC7191192

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mast cell-based molecular subtypes and signature associated with clinical outcome in early-stage lung adenocarcinoma.PMID 32175651Read ↗

Clinical Significance and Regulatory Network of Mast Cells in Early-Stage Lung AdenocarcinomaSemantic proximity Read ↗

Mast cell marker gene signature: prognosis and immunotherapy response prediction in lung adenocarcinoma through integrated scRNA-seq and bulk RNA-seqSemantic proximity Read ↗

Development of a novel prognostic score combining clinicopathologic variables, gene expression, and mutation profiles for lung adenocarcinoma.Semantic proximity Read ↗

Development of a Novel Prognostic Score Combining Clinicopathologic Variables, Gene Expression and Mutationprofiles for Lung AdenocarcinomaSemantic proximity Read ↗

A TP53 Related Immune Prognostic Model for the Prediction of Clinical Outcomes and Therapeutic Responses in Lung Adenocarcinoma.Semantic proximity Read ↗

Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.Semantic proximity Read ↗

Identification of 4 immune cells and a 5-lncRNA risk signature with prognosis for early-stage lung adenocarcinomaSemantic proximity Read ↗

Analysis of Clinical Implications and Immune Landscape in Prognostic Model based on Immune Cell Signatures for Lung Adenocarcinoma PatientsSemantic proximity Read ↗

Systemic immune microenvironment and regulatory network analysis in patients with lung adenocarcinomaSemantic proximity Read ↗

A Novel Gene Signature based on Immune Cell Infiltration Landscape Predicts Prognosis in Lung Adenocarcinoma PatientsSemantic proximity Read ↗

Large-scale bulk RNA-seq analysis defines immune evasion mechanism related to mast cell in gliomasSemantic proximity Read ↗

Identification of a Cancer Testis Antigen-Associated Six-Gene Signature in Lung Adenocarcinoma for the Prediction of Survival and Response to Immune-Checkpoint InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.